Can Personalized Dosing Improve Life With Metastatic Breast Cancer?
Metastatic breast cancer care is increasingly focused on extending survival while preserving quality of life, yet treatment side effects and dosing variability remain major challenges in real-world practice. Differences in patient experience, especially across diverse populations, can make truly personalized treatment difficult to achieve.
In this Teach Me in 10, Dr. Olubukola Ayodele, a consultant medical oncologist at University Hospitals of Leicester, discusses a UK-wide study funded by Breast Cancer Now, the UK’s leading breast cancer charity. The study explores how diverse patients experience therapy side effects and whether personalized dosing could improve outcomes and care equity.
Watch this episode to discover:
- How treatment side effects impact daily life in metastatic breast cancer
- Why personalized dosing is gaining attention in oncology care
- How real-world evidence can improve equity and treatment decisions
- Project Optimus: Reforming the Dose Optimization and Dose Selection Paradigm in Oncology
- New Paradigm in Dose-Finding Trials: Patient-Specific Dosing and Beyond Phase I
- Palbociclib With Letrozole in Postmenopausal Women With ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial
- Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse
- The Drug-Dosing Conundrum in Oncology—When Less Is More
